Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 6.226
Filtrar
1.
Dermatol Online J ; 30(1)2024 Mar 15.
Artigo em Inglês | MEDLINE | ID: mdl-38762858

RESUMO

Tumor necrosis factor (TNF) inhibitors may paradoxically induce pustular eruptions, most of which are classified as pustular psoriasis. Amicrobial pustulosis of the folds (APF) is a much rarer entity that was recently recognized to occur in the setting of chronic anti-TNF therapy and inflammatory bowel disease, with 12 existing cases in the literature. Amicrobial pustulosis of the folds is a neutrophilic dermatosis characterized by aseptic pustules involving the major and minor skin folds, genital regions, and scalp. Herein, we report an additional case of paradoxical APF induced by chronic infliximab therapy in a patient with Crohn disease.


Assuntos
Doença de Crohn , Infliximab , Humanos , Infliximab/efeitos adversos , Infliximab/uso terapêutico , Doença de Crohn/tratamento farmacológico , Doença de Crohn/complicações , Adulto , Dermatopatias Vesiculobolhosas/induzido quimicamente , Dermatopatias Vesiculobolhosas/patologia , Masculino , Feminino , Fator de Necrose Tumoral alfa/antagonistas & inibidores
3.
Exp Dermatol ; 33(5): e15095, 2024 May.
Artigo em Inglês | MEDLINE | ID: mdl-38742822

RESUMO

Limited data exist on the factors associated with hospitalization and mortality in Asian inpatients with autoimmune bullous dermatoses (AIBDs). This study aimed to elucidate the risk factors affecting hospitalization and mortality rates in Asian patients with AIBDs. A retrospective analysis of patients with AIBDs treated at Siriraj Hospital during a 17-year period was performed using the International Classification of Diseases 10th revision codes. The characteristics of inpatients and outpatients were compared, and mortality rates and associated factors were identified. The study included 360 AIBD patients (180 inpatients, 180 outpatients). Inpatients were significantly younger than outpatients. The identified risk factors for hospitalization were malignancy (odds ratio [OR] 2.83, 95% confidence interval [CI] 1.13-8.04; p = 0.034), moderate to severe disease (OR 2.52, 95% CI 1.49-4.34; p < 0.001), systemic corticosteroid use ≥15 mg/day (OR 2.27, 95% CI 1.21-4.41; p = 0.013) and oral cyclophosphamide treatment (OR 9.88, 95% CI 3.82-33.7; p < 0.001). Kaplan-Meier analysis revealed mortality rates of 26%, 36% and 39% for inpatients with pemphigus at 1, 3 and 5 years, respectively. For inpatients with pemphigoid, the corresponding rates were 28%, 38% and 47%. Infections, particularly pneumonia, were the predominant cause of death in both conditions. This study confirmed that both Asian ethnicity and healthcare disparities may be correlated with adverse outcomes in patients with AIBDs. Pemphigus mortality rates were substantially greater in Asian patients than in Caucasian patients. Continuous monitoring of factors contributing to hospitalization and mortality is imperative to improve treatment outcomes.


Assuntos
Povo Asiático , Doenças Autoimunes , Hospitalização , Dermatopatias Vesiculobolhosas , Humanos , Estudos Retrospectivos , Feminino , Masculino , Pessoa de Meia-Idade , Idoso , Dermatopatias Vesiculobolhosas/tratamento farmacológico , Dermatopatias Vesiculobolhosas/mortalidade , Doenças Autoimunes/mortalidade , Doenças Autoimunes/tratamento farmacológico , Adulto , Fatores de Risco , Ciclofosfamida/uso terapêutico , Idoso de 80 Anos ou mais , Corticosteroides/uso terapêutico , Imunossupressores/uso terapêutico , Neoplasias/mortalidade , Adulto Jovem , Estimativa de Kaplan-Meier , Fatores Etários
5.
Rev Med Suisse ; 20(867): 638-647, 2024 Mar 27.
Artigo em Francês | MEDLINE | ID: mdl-38563538

RESUMO

Auto-immune bullous diseases (AIBD) are rare in children. Although their pathogenesis is similar to their adult counterpart, there are differences in the clinical presentation. Moreover certain AIBD prevail at certain ages. There are no guidelines for the treatment of AIBD specific for children. In this review the recent literature is summarised with attention to recent data including diagnostic criteria. We also propose a treatment algorithm.


Les maladies bulleuses auto-immunes (MBAI) sont rares chez les enfants. Bien que la pathogenèse soit similaire à celle de l'adulte, il existe des différences concernant la présentation clinique et la prévalence des MBAI selon l'âge. À ce jour, il n'y a pas de recommandations spécifiques pour leur prise en charge chez l'enfant. Dans cet article, nous présentons une revue des données actuelles, des critères diagnostiques et proposons un algorithme de prise en charge.


Assuntos
Doenças Autoimunes , Dermatopatias Vesiculobolhosas , Criança , Humanos , Algoritmos , Doenças Autoimunes/diagnóstico , Doenças Autoimunes/terapia , Dermatopatias Vesiculobolhosas/diagnóstico , Dermatopatias Vesiculobolhosas/patologia
8.
Front Immunol ; 15: 1337799, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38571950

RESUMO

Generalized Pustular Psoriasis (GPP) is a dermatological autoinflammatory disease that rarely occurs in children and is associated with complex genetic factors. GPP pathogenesis has been associated with mutations in IL36RN gene, which encodes an interleukin-36 receptor antagonist. GPP usually occurs without a history of psoriasis in the patients or their family members. This case report describes the clinical course of a 3-year-old toddler with GPP. The diagnosis of GPP was confirmed through a comprehensive series of examinations, and genetic testing revealed an IL36RN mutation, providing further insight into the genetic basis of the condition. This case highlights the importance of a genetic perspective for diagnosing GPP, particularly in children.


Assuntos
Psoríase , Dermatopatias Vesiculobolhosas , Humanos , Pré-Escolar , Interleucinas/genética , Psoríase/diagnóstico , Psoríase/genética , Psoríase/patologia , Mutação , Testes Genéticos , Doença Aguda , Doença Crônica , Dermatopatias Vesiculobolhosas/genética
10.
BMJ Case Rep ; 17(3)2024 Mar 19.
Artigo em Inglês | MEDLINE | ID: mdl-38508599

RESUMO

Pustular psoriasis of pregnancy (PPP) is a rare variant of generalised pustular psoriasis occurring during or after pregnancy. PPP can have significant maternal and fetal morbidity if left untreated. In this case report, we present a pregnant woman with this rare cutaneous disorder and how it was treated. Due to the limited available evidence regarding the treatment of PPP, we describe the treatment that was given based on the clinical manifestations and severity of the disease.


Assuntos
Exantema , Psoríase , Dermatopatias Vesiculobolhosas , Gravidez , Feminino , Humanos , Psoríase/diagnóstico , Psoríase/tratamento farmacológico , Pele , Cuidado Pré-Natal
11.
Genes (Basel) ; 15(3)2024 Feb 23.
Artigo em Inglês | MEDLINE | ID: mdl-38540337

RESUMO

Pustular skin diseases, with pustular psoriasis (PP) being the prototype, are immune-mediated diseases characterized by the presence of multiple pustules, resulting from neutrophil accumulation in the layer of epidermis. Sterile skin pustular eruption, like PP, is also observed in 20-30% of patients with adult-onset immunodeficiency syndrome (AOID) and anti-interferon γ autoantibodies (IFN-γ), leading to challenges in classification and diagnosis. While the mechanism underlying this similar phenotype remains unknown, genetic factors in relation to the immune system are suspected of playing an important role. Here, the association between human leukocyte antigen (HLA) genes, which play essential roles in antigen presentation, contributing to immune response, and the presence of skin pustules in AOID and PP was revealed. HLA genotyping of 41 patients from multiple centers in Thailand who presented with multiple sterile skin pustules (17 AOID patients and 24 PP patients) was conducted using a next-generation-sequencing-based approach. In comparison to healthy controls, HLA-B*13:01 (OR = 3.825, 95%CI: 2.08-7.035), C*03:04 (OR = 3.665, 95%CI: 2.102-6.39), and DQB1*05:02 (OR = 2.134, 95%CI: 1.326-3.434) were significantly associated with the group of aforementioned conditions having sterile cutaneous pustules, suggesting a common genetic-related mechanism. We found that DPB1*05:01 (OR = 3.851, p = 0.008) and DRB1*15:02 (OR = 3.195, p = 0.033) have a significant association with pustular reaction in AOID patients, with PP patients used as a control. A variant in the DRB1 gene, rs17885482 (OR = 9.073, p = 0.005), was observed to be a risk factor for PP when using AOID patients who had pustular reactions as a control group. DPB1*05:01 and DRB1*15:02 alleles, as well as the rs17885482 variant in the DRB1 gene, were proposed as novel biomarkers to differentiate PP and AOID patients who first present with multiple sterile skin pustules without known documented underlying conditions.


Assuntos
Psoríase , Dermatopatias Vesiculobolhosas , Adulto , Humanos , Antígenos de Histocompatibilidade Classe II , Antígenos HLA/genética , Psoríase/diagnóstico , Psoríase/genética , Autoanticorpos
12.
J Dermatolog Treat ; 35(1): 2331785, 2024 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-38531388

RESUMO

AIM: This case study aims to report the efficacy and safety of a Janus kinase (JAK) inhibitor in the treatment of generalized eosinophilic pustular folliculitis (EPF). METHODS: We present a case of a 16-year-old Chinese patient who had been suffering from EPF for two years and had shown no response to both topical and systemic glucocorticoids. The patient was subsequently treated with oral tofacitinib at a dosage of 5mg daily. RESULTS: Significant remission of eruption and pruritus was observed in the patient upon treatment with tofacitinib. However, a relapse occurred upon dose reduction. Subsequent switch to the highly selective JAK1 inhibitor upadacitinib resulted in complete recovery, with the patient achieving a symptom-free status after six months. CONCLUSIONS: JAK inhibitors show promise as a potential treatment option for EPF patients who do not respond to traditional therapies.


Assuntos
Eosinofilia , Foliculite , Inibidores de Janus Quinases , Dermatopatias Vesiculobolhosas , Humanos , Adolescente , Inibidores de Janus Quinases/uso terapêutico , Foliculite/tratamento farmacológico , Eosinofilia/tratamento farmacológico , Dermatopatias Vesiculobolhosas/tratamento farmacológico
14.
JAMA Dermatol ; 160(4): 476-477, 2024 Apr 01.
Artigo em Inglês | MEDLINE | ID: mdl-38416455

RESUMO

This case report summarizes the treatment of acrodermatitis continua of Hallopeau with spesolimab in a 9-year-old girl.


Assuntos
Acrodermatite , Exantema , Psoríase , Dermatopatias Vesiculobolhosas , Feminino , Humanos , Acrodermatite/diagnóstico , Acrodermatite/tratamento farmacológico , Anticorpos Monoclonais Humanizados
16.
Dermatol Clin ; 42(2): 307-315, 2024 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-38423689

RESUMO

Sneddon-Wilkinson disease (SWD), IgA pemphigus, and bullous systemic lupus erythematosus (BSLE) are superficial and bullous neutrophilic dermatoses. They are all characterized by sterile neutrophilic infiltrate but differ in the level of skin affected and presence of autoantibodies. Both SWD and IgA pemphigus present with grouped flaccid pustules and have epidermal involvement; it is unclear whether they are distinct or exist on a spectrum of the same disease. IgA pemphigus is distinguished from SWD by positive direct immunofluorescence showing intercellular IgA deposition. BSLE presents with tense bullae, dermal neutrophilic infiltrate, and direct immunofluorescence showing linear IgG deposition along the dermal-epidermal junction.


Assuntos
Lúpus Eritematoso Cutâneo , Lúpus Eritematoso Sistêmico , Pênfigo , Dermatopatias Vesiculobolhosas , Humanos , Pênfigo/diagnóstico , Dermatopatias Vesiculobolhosas/diagnóstico , Pele , Autoanticorpos , Lúpus Eritematoso Sistêmico/complicações , Lúpus Eritematoso Sistêmico/diagnóstico , Imunoglobulina A
17.
Dermatol Clin ; 42(2): 317-328, 2024 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-38423690

RESUMO

Generalized pustular rashes have various etiologies and can be challenging to diagnose and manage at first presentation. The authors provide an in-depth analysis of common pustular skin eruptions including generalized pustular psoriasis (GPP) and acute generalized exanthematous pustulosis, focusing on their pathophysiology, triggers, clinical presentation, diagnostic challenges, and management strategies. The article also highlights recent advances in genetic research and biologic therapies for GPP and the future directions in personalized medicine and prevention strategies.


Assuntos
Pustulose Exantematosa Aguda Generalizada , Psoríase , Dermatopatias Vesiculobolhosas , Humanos , Pustulose Exantematosa Aguda Generalizada/diagnóstico , Pustulose Exantematosa Aguda Generalizada/etiologia , Pustulose Exantematosa Aguda Generalizada/terapia , Psoríase/diagnóstico , Psoríase/terapia , Pele , Dermatopatias Vesiculobolhosas/induzido quimicamente , Dermatopatias Vesiculobolhosas/diagnóstico , Dermatopatias Vesiculobolhosas/terapia , Doença Aguda , Doença Crônica
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...